Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0012833 (dizziness)
 9,689 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Spirogermanium, a heavy metal compound in which germanium has been substituted in an azaspirane ring structure, was studied in 39 patients with advanced malignant neoplasms. Thirty-one patients were considered evaluable for toxic effects of spirogermanium. Transient neurological symptoms occurred in 12 patients (39%), including dizziness or lightheadedness, marked fatigue, visual blurring, ataxia, paresthesia, and nausea. These symptoms could be reduced by infusing the drug over 2 hours rather than over 1 hour. Persistent neurotoxicity in the form of partial loss of taste or extreme weakness was observed in three patients. No evidence of hematologic, renal, or hepatic toxicity was observed. Antitumor activity of spirogermanium was not identified in this group of heavily pretreated patients. Spirogermanium had limited and acceptable toxicity in utilizing a dose of 120 mg/m2 infused over 2 hours, three times weekly.
 ...
PMID:A phase II study of spirogermanium in advanced human malignancy. 390 6

Seven cases of subacute central and peripheral neurologic dysfunction developed in 18 workers employed in the manufacture of reinforced plastic bathtubs. Cases were characterized by weight loss, dizziness, paresthesias, muscle weakness, incontinence, memory loss, and loss of peripheral, color, and night vision. Neuropathies began distally, involved both sensory and motor function, and were associated with prolonged sensory latency, muscle fibrillation, and reduced numbers of functioning motor units. One patient developed posterior lenticular cataracts. Slow improvement occurred on removal from exposure, but residual neuropathies persisted for as long as two years. Epidemiologic investigation disclosed that the first case developed approximately two weeks after introduction of a new plastic foaming agent, 2-t-butylazo-2-hydroxy-5-methylhexane (BHMH). All cases occurred in workers exposed directly to BHMH. No new cases developed after use of BHMH was discontinued. A survey of the firm which produced BHMH and of 68 user firms found two additional clusters of mild neuropathy which may have been caused by BHMH. BHMH was withdrawn from distribution following discovery of these cases. Subsequently, BHMH has been shown in rats to be a potent neurotoxin. Adequate premarket testing could have averted this outbreak.
 ...
PMID:Neurologic dysfunction from exposure to 2-t-butylazo-2-hydroxy-5-methylhexane (BHMH): a new occupational neuropathy. 398 40

New labelling processes installed without adequate ventilation control in an electric motor factory exposed production line workers to toxic gases. Symptoms of eye and respiratory tract irritation together with complaints of headache, fever, chills, dizziness, malaise, general weakness, nausea, and vomiting were widespread. Chest signs, radiographic abnormalities, reduction in ventilatory function, and blood gas abnormalities were found in some cases. Epidemiological analysis of the spatial and temporal distribution of cases supported an exposure effect relationship. Investigations suggested ozone and possibly phosgene and associated trichloroacetyl chlorides as the toxic agents that were generated by an ultraviolet print curing arrangement and perchloroethylene used as a cleaning solvent.
 ...
PMID:An outbreak of illness after occupational exposure to ozone and acid chlorides. 404 87

The use of depot-type injections of the contraceptive medroxyprogesterone acetate (DMPA) was studied in 1132 women for up to 5 1/2 years. Continuation rates, reasons for discontinuation, method failure rates, and bleeding patterns were considered. The women received a dose of 400 mg DMPA in aqueous suspension (injected into the deltoid muscle) every six months. In addition, each patient received an oral dose of .04 mg ethynl estradiol for 10 days each lunar month. Of the original acceptors, 36.4 percent used the method for the full 5 1/2 years. The major reasons for discontinuation of DMPA injections were bleeding problems (including amenorrhea) and such other medical reasons as palpitation, abdominal pain, headache, weakness, and dizziness. A total of 26 women became accidently pregnant while using DMPA during the 5 1/2 years. Advantages of DMPA injections were the simplicity, safety, and effectiveness of the method, and the psychological appeal of an injectable contraceptive.
 ...
PMID:Use-effectiveness of six-month injections of DMPA as a contraceptive. 482 85

2 experimental contraceptive injection programs are reported. 1 method provides for administration of a combined long-acting estrogen-progestogen product once a month, the other uses a long acting progestogen alone once every 90 days. In the once-a-month injection program in Los Angeles 615 patients representing 871 admissions were studied; treatment data are for both 1st and all admissions. Age distribution was 21-25 years. Patients received 150 mg of progestogen/10 mg estrogen injection. 88.1% reported cycles of 22-30 days/on admission. Some results are: For 1st and all admissions average duration of flow was 6.6 days; for 1st admission group complaints consisted of breast tenderness, 46% dysmenorrhea, 61.8%, weakness or dizziness, 42.8%, local reaction to injection, 37.4%. For all admissions, complaints were: breast tenderness, 43.3%, dysmenorrhea, 59.6%, weakness, 40.2%, local reaction, 33%. Reasons for dropout for both groups included rigidity of protocol, about 52%, moved away, 4.5%, extraneous illness, 1.5%; 64.4% of all admissions discontinued treatment due to unrelated reasons. No pregnancies were reported. The once every 90 day injection of medroxyprogesterone acetate given in doses of 150 mg were given to 243 women, of whom 57% were aged 20-29. Some results are: 1) number of days of bleeding ranged from 6-20 days, 2) 4.6% reported nervousness, 3.4% nausea, 2.1% headaches, 3) main reasons for dropouts were moving away, 11.8%, bleeding, 4.6%, and 4) 1/3 resumed ovulation within 1/2 year. Both methods are found to be extremely effective.
 ...
PMID:Present status of injectable contraceptives: results of seven-years study. 550 12

Data from 5 studies recently conducted in Bangladesh regarding dizziness as a major side effect of oral contraceptive (OC) use were reviewed. The Bangladeshi women describe dizziness as "Mata gurai" (headspinning), a sensation of rotary motion unaccompanied by nausea or vomiting. It appears to mimic the characteristics of postural hypotension rather than true vertigo and is often associated with generalized weakness. Both dizziness and weakness were cited by a large proportion of women in study A as reasons for discontinuation, and the 2 symptoms were often linked. Burning sensations, usually in the extremities, also proved to be a frequent cause of discontinuation. In study B, except for dizziness, there was no significant difference between women continuing OC use and those who had stopped use. The incidence of dizziness reported by discontinuers was significantly higher than that reported by continuing users. The case-control health survey used in study C corroborated the view that some complaints associated with OC use were equally common in nonusers, but the incidence of dizziness and eye problems was significantly higher in OC users than in both matched control groups. There were no significant associations found between dizziness and hemoglobin levels or blood pressure in study D. Of those women who took multiple vitamin capsules in study E, 57% reported a lessening of dizzinesss, compared with 69% who received glucose capsules.
 ...
PMID:Dizziness associated with discontinuation of oral contraceptives in Bangladesh. 610 46

A case-control survey of mothers was undertaken in rural Bangladesh to assess the health problems of oral contraceptive users compared with two groups of nonusers. The complaint most often reported was weakness--more than 80% of all women surveyed. Significantly more pill users than nonusers reported experiencing dizziness and eye problems. However, only one fifth of dizziness complaints among pill users could be attributed to the pill. Although more pill users reported a decrease in lactation, a greater problem among the control group was total cessation of lactation related to a subsequent pregnancy. Therefore, in this context the pill may postpone weaning more often than it reduces lactation. That few women choose to use oral contraceptives in the early postpartum period, when a reduction in breast milk would be most hazardous to the child, contributes to this favorable balance. The attitude toward early termination of pregnancy was positive for 61% of pill users and 34% of nonusers. It is likely that abortion services would be favorably received in this traditional society.
 ...
PMID:Oral contraceptives and family health in rural Bangladesh. 610 71

34 patients have been controlled after beta-blocking therapy, for a mean period of 5 years. Symptoms and evolution: syncope disappeared, angoy passed from 47% to 23%, dyspnea from 65% to 47%, dizziness from 70% to 54%, weakness from 30% to 37%. A systolic murmur was present in 75% of the cases. Two patients died by heart failure. Phonocardiogram: the systolic murmur was unchanged, like the carotid pulse. Paradoxical splitting of the 2 degrees sound was more frequent, atrial sound unimodified, isometric contraction shortened (60%) and the Q-1 degree sound interval prolonged (90%). Electrocardiogram: 1 degree A/V block appeared in 24% of the cases, complete A/V block in 9%, atrial fibrillation in 3%. Left atrial enlargement was more frequent; left ventricular hypertrophy unchanged. Heart catheterization (10 cases, after a mean period of 5.5 years): left ventricular pressure gradient passed from 80% to 90%; a low cardiac index from 20% to 30%; telediastolic pressure of left ventricle was unmmodified in 10% of cases, more elevated in 50%, less elevated in 40%. Chest X ray: cardiac size was unchanged in 65% of cases, enlarged in 32%; smaller in 3%. In conclusion, symptoms improved in most of the patients; no case of sudden death was observed. Some data however show that the evolution of the myocardiopathy goes on to congestive heart failure and arise doubts on the real usefullness of beta-blocking drugs in the disease.
 ...
PMID:[beta-Blocking therapy in obstructive hypertrophic cardiomyopathy. Long term results (author's transl)]. 610 83

The clinical, electrocardiographic, pharmacologic, electrophysiologic and Holter monitoring findings are described in four patients with autonomic sinus node dysfunction and one patient with autonomic binodal disease. All showed cerebral symptoms, and had attacks of dizziness, weakness, near-syncope or syncope. After a pharmacologic autonomic blockade with propranolol and atropine, all patients had normal intrinsic heart rates. Electrophysiological studies revealed normal corrected intrinsic node recovery time (less than or equal to 240 msec) a gradual return to the basic cycle length in the secondary postpacing cycles after autonomic blockade, and no intrinsic paroxysmal atrioventricular block. Continuous ECG monitoring (1-3 X 24 hours) revealed severe sinus bradycardia, SA-block, severe sinus arrest, cardiac standstill, atrial fibrillation and in two patients associated AV-block. Autonomic blockade with electrophysiological studies exclude the intrinsic involvement of the sinoatrial and atrioventricular node. Holter monitoring is the best method for assessing the autonomic neurovegetative component of dysrhythmias. Therapy regarding isolated autonomic sinus node dysfunction depended on the pathomechanisms of rhythm disorders: two patients received permanent pacemakers, antiarrhythmic drugs were applied in the case of two patients, and etiological treatment in the case of one. During the follow-up, all patients became symptom-free.
 ...
PMID:Autonomic sinus node dysfunction and its treatment. 633 99

1. Beta dimethylaminoethyl benzhydryl ether hydrochloride (Benadryl) is a member of a new group of pharmacologically active antihistamine drugs. 2. Its use in amounts of 50 to 100 mg. given orally one to five times daily to a diverse group of 18 patients with both acute and chronic urticaria is reported. 3. Eleven patients experienced prompt relief of symptoms as long as the drug was taken. Three had definite and real improvement, and many of the wheals which did appear were not pruritic. Four patients were not benefited. 4. The drug has a wide margin of safety, and the only toxic manifestations noted were drowsiness and muscular aching (2 cases) and dizziness, weakness and vertigo (1 case). No cumulative toxic symptoms were noted in patients who ingested the drug as long as six or seven months. All toxic symptoms promptly disappeared when the drug was discontinued. 5. The effect is palliative, and in many patients the urticaria recurred when the administration of the drug was discontinued. 6. Since an antihistamine drug seems to be effective in controlling urticaria, it may be assumed that this is further indirect evidence that histamine is a factor in the production of urticaria.
 ...
PMID:Centennial paper: Beta dimethylaminoethyl benzhydryl ether hydrochloride (benadryl) in treatment of urticaria by Arthur C. Curtis and Betty Brechner Owens. 634 40


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>